Work

Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Table 2 describes the adverse events with corresponding risk differences between treatment arms during consolidation 1 of pivotal trial ALFA-0701.

DOI: 10.1158/1078-0432.22470141.v1

Authors: Emily Y. Jen, Chia-Wen Ko, Jee Eun Lee, Pedro L. Del Valle, Antonina Aydanian, Charles Jewell, Kelly J. Norsworthy, Donna Przepiorka, Lei Nie, Jiang Liu, Christopher M. Sheth, Marjorie Shapiro, Ann T. Farrell, Richard Pazdur

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361817594

Cites:

Cited by:

Related to: 10